%0 Journal Article
%T Current landscape of CD3 bispecific antibodies in hematologic malignancies.
%A Kassner J
%A Abdellatif B
%A Yamshon S
%A Monge J
%A Kaner J
%J Trends Cancer
%V 10
%N 8
%D 2024 Aug 10
%M 38987076
%F 19.161
%R 10.1016/j.trecan.2024.06.001
%X Over the past 30 years the incorporation of monoclonal antibody (mAb) treatments into the management of hematologic malignancies has led to significant improvements in patient outcomes. The key limitation of mAb treatments is the necessity for target antigen presentation on major histocompatibility complex (MHC) and costimulatory molecules to elicit a cytotoxic immune response. With the advent of bispecific antibodies (BsAbs), these limitations can be overcome through direct stimulation of cytotoxic T cells, thus limiting tumor cell evasion. BsAbs are rapidly being incorporated into treatment regimens for hematologic malignancies, and there are now seven FDA-approved treatments in this class, six of which have been approved in the past year. In this review we describe the function, complications, and clinical trial data available for CD3 BsAbs in the treatment of lymphoma, myeloma, and leukemia.